

Investor Webinar: Meet the CEO and Clinical Program Update

Paradigm Biopharmaceuticals Ltd (ASX: PAR) (“Paradigm” or “the Company”), a clinical stage biopharmaceutical company focussed on repurposing existing molecules for new indications with unmet clinical needs, is pleased to announce it will hold an investor webinar on Thursday 21 July 2022 at 11am AEST with new CEO Marco Polizzi and Chief Medical Officer, Dr Donna Skerrett. Mr Polizzi and Dr Skerrett will be in Australia through July conducting several meetings with Paradigm key stakeholders.

The webinar will discuss:

- Introduction of Mr Polizzi ,
- Clinical program update for osteoarthritis and MPS.

Please register for the webinar at the following link:

https://us02web.zoom.us/webinar/register/WN_W_Zh6750RaiC2Oda0t32SQ

Investors are invited to send questions prior to the webinar to:

investorrelations@paradigmbiopharma.com.

After registering, you will receive a confirmation email about joining the webinar. A recording will be available at the same link above shortly after the conclusion of the session on the Paradigm website.

A copy of the presentation for the webinar is available via the paradigm website,

<https://paradigmbiopharma.com/performance-progress/#announcements>.

About Paradigm Biopharmaceuticals

Paradigm Biopharmaceuticals LTD (ASX: PAR) is a late-stage drug development company with the mission to develop and commercialise Pentosan Polysulfate Sodium for the treatment of pain associated with musculoskeletal disorders driven by injury, inflammation, aging, degenerative disease, infection, or genetic predisposition. Paradigm is also exploring proof-of-concept studies for the use of PPS (Pentosan Polysulfate Sodium) in respiratory and heart failure indications.

Authorised for release by the Paradigm Board of Directors.

To learn more please visit: www.paradigmbiopharma.com

FOR FURTHER INFORMATION PLEASE CONTACT:

Simon White

Director of Investor Relations

Tel: +61 404 216 467

Paradigm Biopharmaceuticals Ltd

ABN: 94 169 346 963

Level 15, 500 Collins St, Melbourne, VIC, 3000, AUSTRALIA

Email: investorrelations@paradigmbiopharma.com